This clinical trial is focused on studying the effects of a treatment for depression, specifically targeting patients who undergo Electroconvulsive Therapy (ECT). The treatment being tested is a medication called Rivastigmine, which is delivered through a transdermal patch, meaning it is applied to the skin. The study aims to see if Rivastigmine can help improve cognitive functions, such as memory and thinking skills, after ECT, making the therapy more acceptable and easier to tolerate for patients.

The trial will also explore whether it is possible to predict how well a patient will respond to ECT using clinical characteristics and EEG (a test that measures electrical activity in the brain). This could help avoid unnecessary ECT treatments for those unlikely to benefit from it. Participants in the study will receive either the Rivastigmine patch or a placebo patch, which looks the same but contains no active medication. The study will monitor changes in cognitive abilities and other health measures over time to assess the effectiveness of Rivastigmine.

By participating in this study, researchers hope to develop a method to predict ECT response and reduce its cognitive side effects, potentially improving the quality of life for patients with severe depression. The study will also investigate various factors, such as speech patterns and changes in blood and DNA, to see if they can predict the effects of ECT and Rivastigmine. The ultimate goal is to create a comprehensive prediction method to enhance treatment outcomes for depression.